Jack Cuzick, PhD, of Queen Mary University of London, discusses the substantially greater benefits of anastrozole as compared with tamoxifen in terms of preventing breast cancer, with no increase in fractures or other reported serious side effects (Abstract GS4-04). Nicholas C. Turner, MD, PhD, of The Royal Marsden NHS Foundation Trust, discusses findings…
Ongoing efforts to rein in government spending have been described as a “chainsaw for bureaucracy.” It’s an apt metaphor for the haphazard budget cuts that…
In extended follow-up of the phase II LITESPARK-004 trial reported in The Lancet Oncology, Srinivasan et al looked at the use of belzutifan and outcomes…
The French phase II PANACHE01-PRODIGE48 trial investigated the feasibility and efficacy of neoadjuvant mFOLFIRINOX and FOLFOX in patients with resectable pancreatic adenocarcinoma.
New protocols for endocrine tumors and updated existing protocols for breast cancer diagnoses are now available from the College of American Pathologists (CAP).
“Although multiple agents targeting PD-1 have been approved as second-line treatment for esophageal squamous cell carcinoma, only a fraction of patients derive long-term survival. Hence,…
The French phase II PANACHE01-PRODIGE48 trial investigated the feasibility and efficacy of neoadjuvant mFOLFIRINOX and FOLFOX in patients with resectable pancreatic adenocarcinoma.
The phase II Neo-N trial investigated the activity of two differing schedules of neoadjuvant nivolumab initiation—lead-in or concurrent—with 12 weeks of carboplatin and paclitaxel in…
Patients with active cancer who developed venous thromboembolism (VTE) and were treated with anticoagulants for at least 6 months, followed by an additional 12 months…
The FDA today approved a dual immunotherapy combination for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC).
The use of a circulating tumor DNA liquid biopsy to guide colorectal cancer treatment in the adjuvant setting may not compromise outcomes despite allowing many…
